Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata

The document discussed the potential of Janus Kinase (JAK) inhibitors, such as ruxolitinib and tofacitinib, as treatments for Alopecia Areata (AA), an autoimmune disease causing hair loss. Clinical studies indicated that these inhibitors could reverse AA symptoms by reducing CD8+ cell infiltrates and normalizing IFN-gamma gene expression. However, the broad spectrum of side effects and patient heterogeneity required careful monitoring, especially in young patients. Future research was recommended to focus on enhancing follicular penetration and reducing systemic absorption for safer and more effective topical treatments.